INCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AG

Financial Performance:

• The transcript does not disclose specific financial metrics such as revenue, GAAP earnings, cash flow, debt levels, or deferred revenue for the reporting period.
• Emphasis is placed on the commercial potential of the pipeline, targeting approximately 250,000 new patients annually across the three core programs (anal cancer, colorectal cancer, pancreatic cancer, and ovarian cancer).
• The company holds one approved commercial product, Zioptin (likely a typo in transcript for a PD-1 inhibitor, though the name "Zioptin" is not a standard known asset; context suggests an approved anal cancer therapy), which serves as a foundation for the solid tumor franchise.

Guidance and Future Outlook:

• Top-line data for the Phase 3 DAWN-303 study (734 in pancreatic cancer) is expected in 2028.
• Top-line data for the Phase 3 Nexera study (890 in colorectal cancer) is expected in 2029.
• The company plans to initiate the Phase 3 adjuvant study for 734 in pancreatic cancer and the pivotal Phase 3 study for 734 in colorectal cancer (START-001 or similar) in the first half of 2027.
• Strategic goal is to advance therapies into earlier lines of treatment, specifically first-line settings and adjuvant settings, to maximize patient benefit and commercial opportunity.

Business Segments and Product Lines:

• Program 890 (INCB033890): A TGF-beta R2 x PD-1 bispecific antibody. Primary indication is microsatellite stable (MSS) colorectal cancer (MSS-CRC).
  • Phase 3 Nexera study (890 + FOLFOX/BEV vs. placebo) is enrolling well (N=700) with primary endpoint of Progression-Free Survival (PFS).
  • An adjuvant proof-of-concept study is launching for ctDNA-positive patients post-resection, with a primary endpoint of ctDNA clearance.
  • Additional expansion into head and neck, ovarian, and non-small cell lung cancer is ongoing or planned.
• Program 734 (INCB0161734): A G12D mutant-specific small molecule on-off inhibitor. Primary indications are Pancreatic Ductal Adenocarcinoma (PDAC) and KRAS G12D-mutant colorectal cancer.
  • Phase 3 DAWN-303 study in first-line PDAC is active; data shows high response rates (69-89%) and PFS (80-90% at 6 months) in combination with Gem/Nab-paclitaxel or mFOLFIRINOX.
  • Phase 3 study in 2nd/3rd line colorectal cancer (734 + Cetuximab) is planned for H1 2027, showing 36% ORR vs. <5% standard of care.
  • Novel collaborations announced with BMS (PRMT5 inhibitor), Synovion (PARP1 inhibitor), and Genmab (Pedocentamab).
• Program 667: CDK2 inhibitor for CCNE1-overexpressing ovarian cancer, currently in pivotal trials.
• Program 890/734: Both discovered and developed internally by the company, reinforcing their R&D capabilities.

Market and Competitive Landscape:

• Colorectal Cancer: Addresses the large MSS population (85% of cases) where immunotherapy has historically failed; current standard of care (FOLFOX/BEV) has ~45-50% ORR and ~10-month median PFS.
• Pancreatic Cancer: 40% of tumors harbor KRAS G12D; current standard of care has ~20-30% ORR and ~10-12 month median OS.
• Competition: Compares data favorably to Sotorasib/Adagrasib (KRAS G12C inhibitors) and other KRAS G12D programs (AMG-510, MRTX1133), noting its unique "on-off" mechanism and potential for broader coverage.
• Differentiation: Highlights the unique bispecific mechanism of 890 which spares normal tissue toxicity compared to systemic TGF-beta inhibitors, and the "on-off" mechanism of 734 which may provide more durable inhibition than "on-only" inhibitors.

Risks and Challenges:

• Safety Concerns: Rare cases of myocarditis (approx. 1%) observed in 890 program, though deemed consistent with background rates for PD-1 inhibitors; manageable GI toxicity (nausea, vomiting, diarrhea) for 734, requiring proactive management.
• Enrollment and Timing: Reliance on completing enrollment in 2027 and delivering data in 2028-2029; potential delays in regulatory approval or further development hurdles.
• Resistance Mechanisms: Potential for escape mutations (e.g., upregulation of other pathways) noted in post-treatment biopsies.
• Competitive Pressure: A crowded space with multiple G12D inhibitors and TGF-beta/PD-1 bispecifics in development; risk of commoditization if efficacy differences are not clear.

Management Commentary and Tone:

• Tone: Highly confident and optimistic, emphasizing that the presented data "substantially de-risks" the ongoing pivotal trials.
• Confidence: Management expressed strong conviction in the biological rationale and clinical data, stating they have not seen a better program from competitors.
• Strategic Focus: Reiterated commitment to GI oncology as a core franchise, aiming to establish leadership in KRAS G12D and TGF-beta inhibition.
• Internal Capability: Pride expressed in the fact that both lead programs were discovered and developed in-house.

Analyst Questions and Answers:

• Competitive Differentiation (734): Management emphasized the "on-off" inhibitor mechanism allows for maximal inhibition across the dose interval compared to "on-only" inhibitors, potentially leading to deeper and more durable responses.
• Chemotherapy Role: Management expects chemotherapy to remain a backbone in first-line settings for the near term, though targeted combinations (e.g., with PRMT5 inhibitors) may eventually displace it in specific populations.
• Combination Strategies: No plans for a KRAS pan-RAS inhibitor combination at this time; focus remains on established synergies (Cetuximab, PRMT5, PARP1, Pedocentamab).
• Brain Penetration: Confirmed that 734 has demonstrated brain penetration in preclinical models.
• Risk Management (890): Addressed myocarditis concerns by noting the incidence matches background rates for PD-1 inhibitors; confirmed safety and tolerability of the bispecific construct.
• First-Mover Advantage: Acknowledged the importance of early market entry, particularly for managing toxicity profiles and establishing standard-of-care protocols, but emphasized that clinical differentiation (efficacy/durability) is the ultimate driver.
• Study Endpoints: Confirmed Phase 3 studies are powered to detect statistically and clinically significant improvements in PFS and OS; interim ORR analyses may support accelerated approval if criteria are met.

Other Key Points:

• Mechanism of Action: 890's bispecific design binds PD-1 on immune cells and TGF-beta R2 on the tumor microenvironment, sparing normal tissues and reducing systemic toxicity. 734 binds the KRAS G12D switch-II pocket with picomolar affinity.
• Biomarkers: Strong correlation observed between ctDNA clearance and disease-free survival in the adjuvant setting for 890; profound reduction in mutant allele VAF (Variant Allele Frequency) correlates with response in 734 trials.
• Global Reach: Studies are designed with global enrollment to ensure broad representation of patient populations (right-sided vs. left-sided tumors).
• Future Partnerships: Announced new collaborations with BMS, Synovion, and Genmab to expand the combination toolkit for 734 and 890.